Incorporating the Venous Excess Ultrasound Score (VExUS Score) Into Contemporary Haemodynamic Risk Assessment in Pulmonary Arterial Hypertension: The INVEXUS-PAH Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

86 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-05-07

Study Completion Date

2025-11-21

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This prospective observational study aims to evaluate the relationship between the Venous Excess Ultrasound Score (VEXUS) and the ESC/ERS 2022 simplified four-strata risk assessment model in adult patients with World Health Organization (WHO) Group 1 pulmonary arterial hypertension (PAH). The study investigates whether VEXUS can enhance risk stratification and predict haemodynamic congestion by correlating VEXUS with functional, biochemical, and invasive haemodynamic parameters.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

VExUS in Ards Patients and Association with AKI

NCT06805409

Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)

RECRUITING

VExUS Combined With CVP to Predict Clinical Outcomes in Sepsis Participants

NCT06524622

Sepsis Acute Kidney Injury

RECRUITING

Prevalence of Venous conGestion and Its Association With Renal Injuries Evaluated by the VExUS Score On Admission With UltraSound in Patients With Cardiogenic Pulmonary Edema

NCT05881603

Cardiogenic Acute Pulmonary Edema

UNKNOWN

Treatment According to Venous Excess Ultrasound Score in Patients With Heart Failure

NCT06341816

Heart Failure Acute Kidney Injury

NOT_YET_RECRUITING NA

Performance Evaluation of Clinical Ultrasound in Management of Acute Pulmonary Edema in Elderly Patient

NCT02638350

Pulmonary Edema Respiratory Distress Syndrome

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Pulmonary arterial hypertension (PAH) is a progressive disorder characterised by increased pulmonary vascular resistance, right ventricular overload, systemic venous congestion, and high mortality. The ESC/ERS 2022 simplified four-strata model (low, intermediate-low, intermediate-high, high risk) guides treatment decisions using WHO functional class, 6-minute walk distance, and BNP/NT-proBNP levels.

However, biochemical markers may be costly or insufficiently sensitive to early haemodynamic deterioration.

VEXUS (Venous Excess Ultrasound Score), a point-of-care ultrasonographic method assessing hepatic, portal, and renal venous Doppler patterns, has shown promise in representing venous congestion.

This study evaluates whether VEXUS correlates with ESC/ERS risk categories and invasive haemodynamic parameters including right atrial pressure, mean pulmonary arterial pressure, pulmonary vascular resistance, cardiac output, and pulmonary output. The study further aims to explore whether integrating VEXUS into PAH follow-up may strengthen risk assessment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Arterial Hypertension (PAH) Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PAH Cohort

Adults with World Health Organization (WHO) Group 1 pulmonary arterial hypertension undergoing non-invasive assessment with the Venous Excess Ultrasound Score (VEXUS) and the ESC/ERS 2022 simplified four-strata risk model during routine clinical follow-up. No intervention is administered; this is an observational cohort with a single study visit in which VEXUS, 6MWT, BNP, WHO-FC and recent haemodynamic parameters are collected.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adults aged ≥18 years
* Established diagnosis of WHO Group 1 pulmonary arterial hypertension (PAH)
* Stable outpatient clinical status at the time of VExUS ultrasonography
* Venous Excess Ultrasound Score (VExUS) evaluation performed with adequate ultrasonographic acoustic windows
* Clinically indicated right heart catheterisation (RHC) performed within ±60 days of VExUS assessment
* Availability of ESC/ERS 2022 simplified risk assessment variables (WHO functional class, BNP/NT-proBNP, and 6-minute walk distance)
* Ability to provide written informed consent

Exclusion Criteria

* Pulmonary hypertension other than WHO Group 1, including:

* PH due to left heart disease (WHO Group 2)
* PH due to chronic lung disease or hypoxaemia (WHO Group 3)
* Chronic thromboembolic pulmonary hypertension (CTEPH; WHO Group 4)
* Multifactorial PH (WHO Group 5)
* Eisenmenger syndrome
* Complex or unrepaired congenital heart disease
* Suspected pulmonary veno-occlusive disease (PVOD)
* Pulmonary capillary haemangiomatosis (PCH)
* Acute decompensated right heart failure
* Severe renal dysfunction (eGFR \<30 mL/min/1.73 m²)
* Severe hepatic impairment (Child-Pugh Class C)
* Congestive hepatopathy
* Active infection
* Pregnancy
* Inability or unwillingness to provide informed consent
* Poor ultrasonographic acoustic window preventing adequate VExUS scoring

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No